Multi-omics reveals novel prognostic implication of SRC protein expression in bladder cancer and its correlation with immunotherapy response

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA A Cancer J Clin. 2020;70(1):7–30.
   PubMed Web of Science ®Google Scholar
• Bansal N, Gupta A, Sankhwar SN. Proteometabolomics of bladder cancer: current and future prospects. Cancer Biomarkers: Section A Dis Markers. 2015;15(4):339–348.
   PubMed Web of Science ®Google Scholar
• Miyake M, Owari T, Hori S, et al. Emerging biomarkers for the diagnosis and monitoring of urothelial carcinoma. Res Rep Urol. 2018;10:251–261.
   PubMed Web of Science ®Google Scholar
• Berdik C. Bladder cancer: 4 big questions. Nature. 2017;551(7679):S51.
   PubMed Web of Science ®Google Scholar
• Lenis AT, Lec PM, Chamie K, et al. Bladder cancer: a review. JAMA. 2020;324(19):1980–1991.
   PubMed Web of Science ®Google Scholar
• Giridhar KV, Kohli M. Management of muscle-invasive urothelial cancer and the emerging role of immunotherapy in advanced urothelial cancer. Mayo Clin Proc. 2017;92(10):1564–1582.
   PubMed Web of Science ®Google Scholar
• Goswami S, Chen Y, Anandhan S, et al. ARID1A mutation plus CXCL13 expression act as combinatorial biomarkers to predict responses to immune checkpoint therapy in mUCC. Sci Transl Med. 2020;12(548):eabc4220.
   PubMed Web of Science ®Google Scholar
• Necchi A, Madison R, Raggi D, et al. Comprehensive assessment of immuno-oncology biomarkers in adenocarcinoma, urothelial carcinoma, and squamous-cell carcinoma of the bladder. Eur Urol. 2020;77(4):548–556.
   PubMed Web of Science ®Google Scholar
• Chan TA, Yarchoan M, Jaffee E, et al. Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic. Ann Oncol. 2019;30(1):44–56.
   PubMed Web of Science ®Google Scholar
• van Dijk N, Funt SA, Blank CU, et al. The cancer immunogram as a framework for personalized immunotherapy in urothelial cancer. Eur Urol. 2019;75(3):435–444.
   PubMed Web of Science ®Google Scholar
• D’Andrea D, Soria F, Zehetmayer S, et al. Diagnostic accuracy, clinical utility and influence on decision-making of a methylation urine biomarker test in the surveillance of non-muscle-invasive bladder cancer. BJU Int. 2019;123(6):959–967.
   PubMed Web of Science ®Google Scholar
• Lenz EM, Bright J, Wilson ID, et al. Metabonomics, dietary influences and cultural differences: a 1H NMR-based study of urine samples obtained from healthy British and Swedish subjects. J Pharm Biomed Anal. 2004;36(4):841–849.
   PubMed Web of Science ®Google Scholar
• Hou T, Zhou L, Wang L, et al. CLCA4 inhibits bladder cancer cell proliferation, migration, and invasion by suppressing the PI3K/AKT pathway. Oncotarget. 2017;8(54):93001–93013.
   PubMedGoogle Scholar
• Kataoka M, Ishibashi K, Kumagai S, et al. Expression and function of LPA1 in bladder cancer. J Urol. 2015;194(1):238–244.
   PubMed Web of Science ®Google Scholar
• Liu Y, Wu X, Wang G, et al. CALD1, CNN1, and TAGLN identified as potential prognostic molecular markers of bladder cancer by bioinformatics analysis. Medicine. 2019;98(2):e13847.
   PubMed Web of Science ®Google Scholar
• Whongsiri P, Pimratana C, Wijitsettakul U, et al. LINE-1 ORF1 protein is up-regulated by reactive oxygen species and associated with bladder urothelial carcinoma progression. Cancer Genomics Proteomics. 2018;15(2):143–151.
   PubMed Web of Science ®Google Scholar
• Lintula S, Hotakainen K. Developing biomarkers for improved diagnosis and treatment outcome monitoring of bladder cancer. Expert Opin Biol Ther. 2010;10(8):1169–1180.
   PubMed Web of Science ®Google Scholar
• Aslam B, Basit M, Nisar MA, et al. Proteomics: technologies and their applications. J Chromatogr Sci. 2017;55(2):182–196.
   PubMed Web of Science ®Google Scholar
• Xu W-H, Xu Y, Tian X, et al. Large-scale transcriptome profiles reveal robust 20-signatures metabolic prediction models and novel role of G6PC in clear cell renal cell carcinoma. J Cell Mol Med. 2020;24(16):9012–9027.
   PubMed Web of Science ®Google Scholar
• Xu W-H, Xu Y, Wang J, et al. Prognostic value and immune infiltration of novel signatures in clear cell renal cell carcinoma microenvironment. Aging (Albany NY). 2019;11(17):6999–7020.
   PubMedGoogle Scholar
• Rahim MAA, Rahim ZHA, Ahmad WAW, et al. Can saliva proteins be used to predict the onset of acute myocardial infarction among high-risk patients? Int J Med Sci. 2015;12(4):329–335.
   PubMed Web of Science ®Google Scholar
• Li X, Li S, Lu M, et al. Proteomic profiling of iron overload-induced human hepatic cells reveals activation of TLR2-mediated inflammatory response. Molecules. 2016;21(3):322.
   PubMed Web of Science ®Google Scholar
• Borrebaeck CAK. Precision diagnostics: moving towards protein biomarker signatures of clinical utility in cancer. Nat Rev Cancer. 2017;17(3):199–204.
   PubMed Web of Science ®Google Scholar
• Nishizuka S, Charboneau L, Young L, et al. Proteomic profiling of the NCI-60 cancer cell lines using new high-density reverse-phase lysate microarrays. PNAS. 2003;100(24):14229–14234.
   PubMed Web of Science ®Google Scholar
• Tibes R, Qiu Y, Lu Y, et al. Reverse phase protein array: validation of a novel proteomic technology and utility for analysis of primary leukemia specimens and hematopoietic stem cells. Mol Cancer Ther. 2006;5(10):2512–2521.
   PubMed Web of Science ®Google Scholar
• Wickham H. ggplot2: elegant graphics for data analysis. New York, NY: Springer-Verlag; 2016.
   Google Scholar
• Therneau TM, Grambsch PM. Modeling survival data: extending the Cox model. New York, NY: Springer; 2000.
   Google Scholar
• Friedman J, Hastie T, Tibshirani R. Regularization paths for generalized linear models via coordinate descent. J Stat Softw. 2010;33(1):1–22.
   PubMed Web of Science ®Google Scholar
• Sun D, Wang J, Han Y, et al. TISCH: a comprehensive web resource enabling interactive single-cell transcriptome visualization of tumor microenvironment. Nucleic Acids Res. 2021;49(D1):D1420–D1430.
   PubMed Web of Science ®Google Scholar
• Ritchie ME, Phipson B, Wu D, et al. Limma Powers Differential Expression Analyses for RNA-Sequencing and Microarray Studies. 2015;43(7):7.
   Google Scholar
• Xu W-H, Qu Y-Y, Wang J, et al. Elevated CD36 expression correlates with increased visceral adipose tissue and predicts poor prognosis in ccRCC patients. J Cancer. 2019;10(19):4522–4531.
   PubMed Web of Science ®Google Scholar
• Xu WH, Wu J, Wang J, et al. Screening and identification of potential prognostic biomarkers in adrenocortical carcinoma. Front Genet. 2019;10:821.
   PubMed Web of Science ®Google Scholar
• Franceschini A, Szklarczyk D, Frankild S, et al. STRING V9.1: protein–protein interaction networks, with increased coverage and integration. Nucleic Acids Res. 2012. 41(D1):D808–D815.
   PubMed Web of Science ®Google Scholar
• Smoot ME, Ruscheinski J, Wang P-L, et al. Cytoscape 2.8: new features for data integration and network visualization. Bioinformatics. 2011;27:431–432.
   PubMed Web of Science ®Google Scholar
• Bandettini WP, Kellman P, Mancini C, et al. MultiContrast Delayed Enhancement (MCODE) improves detection of subendocardial myocardial infarction by late gadolinium enhancement cardiovascular magnetic resonance: a clinical validation study. J Cardiovasc Magn Reson. 2012;14(1):83.
   PubMed Web of Science ®Google Scholar
• Yu G, Wang L-G, Han Y, et al. clusterProfiler: an R package for comparing biological themes among gene clusters. OMICS. 2012;16(5):284–287.
   PubMed Web of Science ®Google Scholar
• Xu W-H, Shi S-N, Xu Y, et al. Prognostic implications of Aquaporin 9 expression in clear cell renal cell carcinoma. J Transl Med. 2019;17(1):363.
   PubMed Web of Science ®Google Scholar
• Kakehi Y, Hirao Y, Kim WJ, et al. Bladder Cancer Working Group report. Jpn J Clin Oncol. 2010;40:i57–i64.
   PubMed Web of Science ®Google Scholar
• Wanqing C, Rongshou Z, Peter DB, et al. Cancer statistics in China. CA: Cancer J Clinicians. 2015;66(2):115–132.
   Web of Science ®Google Scholar
• Alireza S, Abdul-aziz K, Leila M, et al. Epidemiologic status of bladder cancer in Shiraz, southern Iran. Asian Pacific J Cancer Prev. 2011;12(5):1323–1327.
   PubMedGoogle Scholar
• Yeung C, Dinh T, Lee J. The health economics of bladder cancer: an updated review of the published literature. PharmacoEconomics. 2014;32(11):1093–1104.
   PubMed Web of Science ®Google Scholar
• Vega-Rubín-de-Celis S. The role of beclin 1-dependent autophagy in cancer. Biology. 2019;9(1):4.
   PubMed Web of Science ®Google Scholar
• Alison MM, Rinako N. The link between PKCalpha regulation and cellular transformation. Immunol Lett. 2005;96(2):155–162.
   PubMed Web of Science ®Google Scholar
• Liu X, Wang P, Zhang C, et al. Epidermal growth factor receptor (EGFR): a rising star in the era of precision medicine of lung cancer. Oncotarget. 2017;8(30):50209–50220.
   PubMedGoogle Scholar
• Fortunato C, Giampaolo T. EGFR antagonists in cancer treatment. New Engl J Med. 2008;358(11):1160–1174.
   PubMed Web of Science ®Google Scholar
• Jean-Charles S, Suresh SR. Osimertinib in EGFR mutation-positive advanced NSCLC. New Engl J Med. 2018;378(13):1262–1263.
   Google Scholar
• Fanny T, Mark V, Jamal D, et al. Annexin1 regulates DC efferocytosis and cross-presentation during Mycobacterium tuberculosis infection. J Clin Invest. 2015;125(2):752–768.
   PubMed Web of Science ®Google Scholar
• Fulvio D'A, Ahmed M, Emilio L, et al. Annexin-1 modulates T-cell activation and differentiation. Blood. 2007;109(3):1095–1102.
   Google Scholar
• Shen Y, Chen X, He J, et al. Axl inhibitors as novel cancer therapeutic agents. Life Sci. 2018;198:99–111.
   PubMed Web of Science ®Google Scholar
• Aita VM, Liang XH, Murty VV, et al. Cloning and genomic organization of beclin 1, a candidate tumor suppressor gene on chromosome 17q21. Genomics. 1999;59(1):59–65.
   PubMed Web of Science ®Google Scholar
• Zheng M-W, Zhang C-H, Chen K, et al. Preclinical evaluation of a novel orally available SRC/Raf/VEGFR2 inhibitor, SKLB646, in the treatment of triple-negative breast cancer. Mol Cancer Ther. 2016;15(3):366–378.
   PubMed Web of Science ®Google Scholar
• Yu G-T, Mao L, Wu L, et al. Inhibition of SRC family kinases facilitates anti-CTLA4 immunotherapy in head and neck squamous cell carcinoma. Cell Mol Life Sci. 2018;75(22):4223–4234.
   PubMed Web of Science ®Google Scholar
• Mao L, Deng W-W, Yu G-T, et al. Inhibition of SRC family kinases reduces myeloid-derived suppressor cells in head and neck cancer. Int J Cancer. 2017;140(5):1173–1185.
   PubMed Web of Science ®Google Scholar
• Inderberg EM, Mensali N, Oksvold MP, et al. Human c-SRC kinase (CSK) overexpression makes T cells dummy. Cancer Immunol Immunother. 2018;67(4):525–536.
   PubMed Web of Science ®Google Scholar